SS 31 Clinical Applications - Conditions Treated and Who Benefits Most

SS 31's clinical relevance spans multiple disease areas because mitochondrial dysfunction is not a single disease. It is a cellular mechanism that contributes to pathology across cardiology, neurology, metabolic medicine, and genetic mitochondrial disorders. When the machinery that produces cellular energy breaks down, the clinical presentation depends on which tissue is most affected and how severely.

Elamipretide (SS 31) received FDA approval under the brand name Stegazo for Barth syndrome associated cardiomyopathy, a genetic condition caused by defective cardiolipin remodeling. Beyond this approved indication, the mechanism of action, stabilizing cardiolipin and restoring electron transport chain efficiency, applies to any condition where mitochondrial dysfunction is a contributing factor.

Key takeaways

Elamipretide received FDA approval as Stegazo for Barth syndrome associated cardiomyopathy, validating its cardiolipin targeting mechanism in a clinical setting
Beyond Barth syndrome, SS 31 is prescribed for chronic fatigue with mitochondrial involvement, cardiovascular conditions where cardiac mitochondrial bioenergetics are impaired, age related mitochondrial decline, and exercise intolerance
The thread connecting all applications is the same: cardiolipin damage leads to impaired ATP production and increased oxidative stress, and SS 31 restores cardiolipin function
SS 31 is not a treatment for symptoms. It addresses the structural mitochondrial dysfunction underlying those symptoms
Patient eligibility depends on clinical assessment, not self diagnosis. Physician evaluation determines whether mitochondrial dysfunction is likely contributing to your specific condition

Is SS-31 Therapy right for you?

Check Eligibility

Cardiovascular Applications

The heart is the most metabolically active organ in the body, beating approximately 100,000 times per day and relying almost entirely on mitochondrial ATP production to sustain contractile function. Cardiac mitochondria make up roughly 30% of cardiomyocyte volume, and their efficiency directly determines cardiac output and functional capacity.

Heart failure, ischemic heart disease, and age related cardiac decline all involve measurable mitochondrial dysfunction. Cardiolipin damage in cardiac mitochondria reduces ATP availability for contraction, increases ROS that further damage cardiac tissue, and contributes to the progressive decline in cardiac function that characterizes these conditions.

SS 31's cardiolipin stabilization in cardiac mitochondria has been studied in heart failure and ischemia reperfusion models, with published data showing improved cardiac output, reduced oxidative damage, and improved functional capacity. The Stegazo FDA approval for Barth syndrome cardiomyopathy validates this cardiac mechanism in a clinical regulatory setting.

For the complete cardiovascular application guide including clinical trial data, see SS 31 for Cardiovascular Function and Heart Health.

Chronic Fatigue and Energy Disorders

Persistent, debilitating fatigue that does not resolve with rest, sleep optimization, or standard interventions often has a mitochondrial component. When skeletal muscle mitochondria are inefficient, the ATP cost of normal daily activity exceeds what the mitochondria can efficiently supply, creating a chronic energy deficit that manifests as fatigue, exercise intolerance, and post exertional malaise.

SS 31 directly addresses this energy deficit by restoring mitochondrial ATP production efficiency in skeletal muscle. Clinical observations show measurable improvements in exercise tolerance and subjective fatigue scores within 2 to 6 weeks.

For the full chronic fatigue application, see SS 31 for Chronic Fatigue and Low Energy..

Who Qualifies for SS 31 Therapy

Patient Scenario	Why SS 31 May Be Appropriate	Assessment Required
Barth syndrome associated cardiomyopathy	FDA approved indication (Stegazo). Direct cardiolipin remodeling defect addressed by SS 31's mechanism	Genetic confirmation and cardiologist involvement
Heart failure or ischemic heart disease	Cardiac mitochondrial dysfunction contributes to impaired contractile function and exercise capacity	Cardiologist evaluation, baseline echocardiography, functional testing
Chronic fatigue with suspected mitochondrial involvement	Persistent fatigue unresponsive to standard interventions may reflect skeletal muscle mitochondrial inefficiency	Physician assessment ruling out other causes, baseline metabolic and mitochondrial markers
Age related mitochondrial decline	Progressive decline in energy, recovery, cognitive function, and physical capacity consistent with age related mitochondrial changes	Physician assessment of symptom profile and treatment goals
Exercise intolerance disproportionate to fitness level	Significant exercise intolerance not explained by cardiovascular or musculoskeletal pathology may reflect mitochondrial ATP limitation	Physician evaluation to rule out cardiac and musculoskeletal causes first

For the complete eligibility criteria and patient assessment guide, see Who Is a Candidate for SS 31 Therapy and Conditions Treated with SS 31 Therapy.

‍

Frequently Asked Questions

Does SS 31 treat the underlying disease or just symptoms?

SS 31 addresses the structural mitochondrial dysfunction (cardiolipin damage) that contributes to symptoms. In conditions where mitochondrial dysfunction is the primary driver, this represents treatment of the underlying mechanism. In conditions where mitochondrial dysfunction is one of several contributing factors, SS 31 addresses that specific component.

Can SS 31 replace my heart failure medications?

No. SS 31 is a complementary therapy that addresses the mitochondrial component of cardiac disease. It does not replace standard of care cardiac medications. All existing prescriptions should continue unless your cardiologist advises otherwise.

Do I need genetic testing before starting SS 31?

Not for most applications. Genetic testing is relevant for suspected Barth syndrome or primary mitochondrial disorders. For age related mitochondrial decline, chronic fatigue, and general applications, physician clinical assessment is sufficient for determining eligibility.

Ready to find out what SS-31 dose is right for you?

Our physicians evaluate your health history, review your blood work, and create a personalized dosing protocol.

Get Started

Disclaimer

This content is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. SS 31 (elamipretide) is available through licensed U.S. compounding pharmacies via physician prescription. Compounded medications are not FDA reviewed for safety, quality, or efficacy as finished products. Consult a licensed healthcare provider before starting, changing, or stopping any treatment. Individual results vary.